Animal models of chemical carcinogenesis: Driving breakthroughs in cancer research for 100 years

Cold Spring Harbor Protocols

Volumn 2015, Issue 10, 2015, Pages 865-875

  Kemp, Christopher J ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CROTON OIL; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYTOCHROME P450; DIETHYLNITROSAMINE; ETHYLNITROSOUREA; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN P27; PROTEIN P53; URETHAN; CARCINOGEN;

ANGIOSARCOMA; ARTICLE; BIOASSAY; BLADDER CANCER; CANCER GROWTH; CANCER RESEARCH; CANCER RISK; CARCINOGENICITY; CHEMICAL CARCINOGENESIS; ENVIRONMENTAL EXPOSURE; EXPERIMENTAL MODEL; GENE MUTATION; GENETIC PREDISPOSITION; GENOTYPE ENVIRONMENT INTERACTION; GOVERNMENT REGULATION; LIVER CANCER; METABOLIC ACTIVATION; NONHUMAN; OVARY CANCER; SKIN CANCER; X RAY; ANIMAL; ANIMAL MODEL; CARCINOGENESIS; CHEMICALLY INDUCED; MOUSE; NEOPLASM;

ANIMALS; CARCINOGENESIS; CARCINOGENS; MICE; MODELS, ANIMAL; NEOPLASMS;

EID: 84943259520     PISSN: 19403402     EISSN: 15596095     Source Type: Journal    
DOI: 10.1101/pdb.top069906     Document Type: Article

References (106)

1. Abel EL, Angel JM, Kiguchi K, DiGiovanni J. 2009. Multi-stage chemical carcinogenesis in mouse skin: Fundamentals and applications. Nat Protoc 4: 1350-1362.
2. Anderson LM. 2004. Introduction and overview. Perinatal carcinogenesis: Growing a node for epidemiology, risk management, and animal studies. Toxicol Appl Pharmacol 199: 85-90.
3. Angel JM, DiGiovanni J. 1999. Genetics of skin tumor promotion. Prog Exp Tumor Res 35: 143-157.
4. Anisimov VN, Ukraintseva SV, Yashin AI. 2005. Cancer in rodents: Does it tell us about cancer in humans? Nat Rev Cancer 5: 807-819.
5. Ashby J. 2001. Expectations for transgenic rodent cancer bioassay models. Toxicol Pathol 29: 177-182.
6. Balmain A. 2002. Cancer as a complex genetic trait: Tumor susceptibility in humans and mouse models. Cell 108: 145-152.
7. Balmain A, Pragnell IB. 1983. Mouse skin carcinomas induced in vivo by chemical carcinogens have a transforming Harvey-ras oncogene. Nature 303: 72-74.
8. Becher OJ, Holland EC. 2006. Genetically engineered models have advantages over xenografts for preclinical studies. Cancer Res 66: 3355-3358, discussion.
9. Berenblum I, Shubik P. 1947. A new, quantitative, approach to the study of the stages of chemical carcinogenesis in the mouse's skin. Br J Cancer 1: 383-391.
10. Bissahoyo A, Pearsall RS, Hanlon K, Amann V, Hicks D, Godfrey VL, Threadgill DW. 2005. Azoxymethane is a genetic background-dependent colorectal tumor initiator and promoter in mice: Effects of dose, route, and diet. Toxicol Sci 88: 340-345.
11. Boyland F. 1969. The correlation of experimental carcinogenesis and cancer in man. Prog Exp Tumor Res 11: 222-234.
12. Brookes P, Lawley PD. 1964. Evidence for the binding of polynuclear aromatic hydrocarbons to the nucleic acids of mouse skin: Relation between carcinogenic power of hydrocarbons and their binding to deoxynucleic acid. Nature 202: 781-784.
13. Brown K, Buchmann A, Balmain A. 1990. Carcinogen-induced mutations in the mouse c-Ha-ras gene provide evidence of multiple pathways for tumour progression. Proc Natl Acad Sci 87: 538-542.
14. Burns PA, Kemp CJ, Gannon JV, Lane DP, Bremner R, Balmain A. 1991. Loss of heterozygosity and mutational alterations of the p53 gene in skin tumors of interspecific hybrid mice. Oncogene 6: 2363- 2369.
15. Busch SE, Gurley KE, Moser RD, Kemp CJ. 2012. ARF suppresses hepatic vascular neoplasia in a carcinogen-exposed murine model. J Pathol 227: 298-305.
16. Busch SE, Gurley KE, Moser R, Kelly-Spratt KS, Liggitt D, Kemp CJ. 2013. p19arf inhibits the growth and malignant progression of carcinogen induced non small cell lung cancer. Oncogene (in press).
17. Chu IM, Hengst L, Slingerland JM. 2008. The Cdk inhibitor p27 in human cancer: Prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 8: 253-267.
18. Cook JW, Hieger I, Kennaway EL, Mayneord WV. 1932. The production of cancer by pure hydrocarbons. R Soc Proc 111: 455-484.
19. Demant P. 2003. Cancer susceptibility in the mouse: Genetics, biology and implications for human cancer. Nat Rev Genet 4: 721-734.
20. Di Cristofano A, De Acetis M, Koff A, Cordon-Cardo C, Pandolfi PP. 2001. Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet 27: 222-224.
21. Dietrich WF, Lander ES, Smith JS, Moser AR, Gould KA, Luongo C, Borenstein N, Dove W. 1993. Genetic identification of Mom-1, a major modifier locus affecting Min-induced intestinal neoplasia in the mouse. Cell 75: 631-639.
22. Doll R, Peto R. 1981. The causes of cancer: Quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst 66: 1191-1308.
23. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356: 215-221.
24. Dragani TA. 2003. 10 years of mouse cancer modifier loci: Human relevance. Cancer Res 63: 3011-3018.
25. Dragani TA, Manenti G, Gariboldi M, De Gregorio L, Pierotti MA. 1995a. Genetics of liver tumor susceptibility in mice. Toxicol Lett 82: 613-619.
26. Dragani TA, Manenti G, Pierotti MA. 1995b. Genetics of murine lung tumors. Adv Cancer Res 67: 83-112.
27. Driessens G, Beck B, Caauwe A, Simons BD, Blanpain C. 2012. Defining the mode of tumour growth by clonal analysis. Nature 488: 527-530.
28. Drinkwater NR, Ginsler JJ. 1986. Genetic control of hepatocarcinogenesis in C57BL/6J and C3H/HeJ inbred mice. Carcinogenesis 7: 1701-1707.
29. Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC, et al. 2012. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486: 353-360.
30. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, Polyak K, Tsai LH, Broudy V, Perlmutter RM, et al. 1996. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27-deficient mice. Cell 85: 733-744.
31. Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ. 1998. The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature 396: 177-180.
32. Findlay GM. 1928. Ultra-violet light and skin cancer. The Lancet ii: 1070- 1073.
33. Forkert PG. 2010. Mechanisms of lung tumorigenesis by ethyl carbamate and vinyl carbamate. Drug Metab Rev 42: 355-378.
34. Frese KK, Tuveson DA. 2007. Maximizing mouse cancer models. Nat Rev Cancer 7: 645-658.
35. Fung VA, Barrett JC, Huff J. 1995. The carcinogenesis bioassay in perspective: Application in identifying human cancer hazards. Environ Health Perspect 103: 680-683.
36. Furth J, Furth OB. 1936. Neoplastic diseases produced in mice by general irradiation with X-rays. Am J Cancer 28: 54-65.
37. Gold LS, Zeiger E. 1997. Handbook of carcinogenic potency and genotoxicity databases. CRC Press, Boca Raton, FL.
38. Goshman LM, Heidelberger C. 1967. Binding of tritium-labeled polycyclic hydrocarbons to DNA of mouse skin. Cancer Res 27: 1678-1688.
39. Greaves M, Maley CC. 2012. Clonal evolution in cancer. Nature 481: 306- 313.
40. Gurley KE, Moser RD, Kemp CJ. 2014a. Induction of lung tumors in mice with urethane. Cold Spring Harb Protoc doi: 10.1101/pdb.prot077446.
41. Gurley KE, Moser RD, Kemp CJ. 2014b. Induction of liver tumors in mice with N-ethyl-N-nitrosourea or N-nitrosodiethylamine. Cold Spring Harb Protoc doi: 10.1101/pdb.prot077438.
42. Gurley KE, Moser RD, Kemp CJ. 2014c. Induction of colon cancer in mice with 1,2-dimethylhydrazine. Cold Spring Harb Protoc doi: 10.1101/pdb. prot077453.
43. Harvey M, McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A, Donehower LA. 1993. Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nat Genet 5: 225-229.
44. Herceg Z. 2007. Epigenetics and cancer: Towards an evaluation of the impact of environmental and dietary factors. Mutagenesis 22: 91-103.
45. Huff J. 1993. Chemicals and cancer in humans: First evidence in experimental animals. Environ Health Perspect 100: 201-210.
46. IARC (International Agency for Research on Cancer). Scientific Publication No. 100. (ed. Tomatis L). Who Press, New York. 1990. Cancer: Causes, occurrence, and control.
47. IOM (Institute of Medicine). 2001. Rebuiliding the unity of health and the environment: A new vision of environmental health for the 21st century workshop summary (ed. Institute of Medicine). National Academy of Sciences, Washington, DC.
48. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA. 1994. Tumor spectrum analysis in p53-mutant mice. Curr Biol 4: 1-7.
49. Jackson EL, Olive KP, Tuveson DA, Bronson R, Crowley D, Brown M, Jacks T. 2005. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res 65: 10280-10288.
50. Jiang W, Ananthaswamy HN, Muller HK, Kripke ML. 1999. p53 protects against skin cancer induction by UV-B radiation. Oncogene 18: 4247- 4253.
51. Jirtle RL, Skinner MK. 2007. Environmental epigenomics and disease susceptibility. Nat Rev Genet 8: 253-262.
52. Kelly-Spratt KS, Gurley KE, Yasui Y, Kemp CJ. 2004. p19Arf suppresses growth, progression, and metastasis of Hras-driven carcinomas through p53-dependent and -independent pathways. PLoS Biol 2: 1138-1149.
53. Kelly-Spratt KS, Philipp-Staheli J, Gurley KE, Hoon-Kim K, Knoblaugh S, Kemp CJ. 2009. Inhibition of PI-3K restores nuclear p27Kip1 expression in a mouse model of Kras-driven lung cancer. Oncogene 38: 3652-3662.
54. Kemp CJ. 2005. Multistep skin cancer in mice as a model to study the evolvability of cancer cells. Sem Cancer Biol 15: 460-473.
55. Kemp CJ, Wheldon T, Balmain A. 1994. p53 deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nat Genet 8: 66-69.
56. Kemp CJ, Donchower LA, Bradley A, Balmain A. 1993. Reduction of p53 gene dosage does not increase initiation or promotion but greatly enhances malignant progression of chemically induced skin tumors. Cell 74: 813-822.
57. Kennaway EL. 1955. The identification of a carcinogenic compound in coal tar. Br Med J ii: 749-752.
58. Kinosita R. 1936. Researches on the carcinogenesis of the various chemical substances. Gann 30: 423-426.
59. Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES, Ono M, Khanam D, Hayday AC, Frohman LA, Koff A. 1996. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell 85: 721-732.
60. Lawley PD. 1994. Historical origins of current concepts of carcinogenesis. Adv Cancer Res 65: 17-111.
61. Lewis BC, Klimstra DS, Socci ND, Xu S, Koutcher JA, Varmus HE. 2005. The absence of p53 promotes metastasis in a novel somatic mouse model for hepatocellular carcinoma. Mol Cell Biol 25: 1228-1237.
62. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K. 2000. Environmental and heritable factors in the causation of cancer-Analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343: 78-85.
63. Liu P, Wang Y, Vikis H, Maciag A, Wang D, Lu Y, Liu Y, You M. 2006. Candidate lung tumor susceptibility genes identified through wholegenome association analyses in inbred mice. Nat Genet 38: 888-895.
64. Lynch CJ. 1926. Studies on the relation between tumor susceptibility and heredity. III. Spontaneous tumors of the lung in mice. J Exp Med 43: 339-355.
65. Magee PN, Barnes JM. 1956. The production of malignant primary hepatic tumours in the rat by feeding dimethylnitrosamine. Br J Cancer 10: 114- 122.
66. Magee PN, Barnes JM. 1967. Carcinogenic nitroso compounds. Adv Cancer Res 10: 163-246.
67. Miller JA. 1991. The need for epidemiological studies of the medical exposures of Japanese patients to the carcinogenic ethyl carbamate (urethane) from 1950 to 1975. Jpn J Cancer Res 82: 1323-1324.
68. Miller JA, Miller EC. 1947. The metabolism and carcinogenicity of p-dimethylaminoazobenzene and related compounds in the rat. Cancer Res 7: 39-41.
69. Miller EC, Miller JA. 1979. Milestones in chemical carcinogenesis. Semin Oncol 6: 445-460.
70. Nagase H, Bryson S, Cordell H, Kemp CJ, Fee F, Balmain A. 1995. Distinct genetic loci control development of benign and malignant skin tumours in mice. Nature Genet 10: 424-429.
71. National Toxicology Program. 2011. 12th Report on Carcinogens. U.S. Department of Health and Human Services Public Health Service National Toxicoloy Program.
72. Nettleship A, Henshaw PS, Meyer HL. 1943. Induction of pulmonary tumors in mice with ethyl carbamate (urethane). J Natl Cancer Inst 4: 309-319.
73. Nowell PC. 1976. The clonal evolution of tumor cell populations. Science 194: 23-28.
74. OTA (Office of Technology Assessment). 1981. Assessment of technologies for determining cancer risks from the environment (ed. Office of Technology Assessment). U.S. Government Printing Office, Washington, DC.
75. Payne SR, Kemp CJ. 2003. p27Kip1(Cdkn1b)-deficient mice are susceptible to chemical carcinogenesis and may be a useful model for carcinogen screening. Toxicol Pathol 31: 355-363.
76. Payne SR, Kemp CJ. 2005. Tumor suppressor genetics. Carcinogenesis 26: 2031-2045.
77. Philipp-Staheli J, Payne SR, Kemp CJ. 2001. p27(Kip1): Regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer. Exp Cell Res 264: 148-168.
78. Philipp-Staheli J, Kim KH, Payne SR, Gurley KE, Liggitt D, Longton G, Kemp CJ. 2002. Pathway-specific tumor suppression. Reduction of p27 accelerates gastrointestinal tumorigenesis in Apc mutant mice, but not in Smad3 mutant mice. Cancer Cell 1: 355-368.
79. Pitot HC. 1983. Contributions to our understanding of the natural history of neoplastic development in lower animals to the cause and control of human cancer. Cancer Surveys 2: 519-538.
80. Poole TM, Chiaverotti TA, Carabeo RA, Drinkwater NR. 1996. Genetic analysis of multistage hepatocarcinogenesis. Prog Clin Biol Res 395: 33-45.
81. Pott P. 1775. Chirugical observations relative to the cataract, the polypus of the nose, the cancer of the scrotum, the different kinds of ruptures and the mortifications of the toes and feet. Hawkes, Clarke, and Collins, London.
82. Pritchard JB, French JE, Davis BJ, Haseman JK. 2003. The role of transgenic mouse models in carcinogen identification. Environ Health Perspect 111: 444-454.
83. Quigley DA, To MD, Perez-Losada J, Pelorosso FG, Mao JH, Nagase H, Ginzinger DG, Balmain A. 2009. Genetic architecture of mouse skin inflammation and tumour susceptibility. Nature 458: 505-508.
84. Quintanilla M, Brown K, Ramsden M, Balmain A. 1986. Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature 322: 78-80.
85. Rall DP. 2000. Laboratory animal tests and human cancer. Drug Metab Rev 32: 119-128.
86. Rehn L. 1895. Uberblasentumoren bei fuchsinarbeiten. Arch Klin Chir 50: 588.
87. Ruddell A, Kelly-Spratt KS, Furuya M, Parghi SS, Kemp CJ. 2008. p19/Arf and p53 suppress sentinel lymph node lymphangiogenesis and carcinoma metastasis. Oncogene 27: 3145-3155.
88. Sasaki T, Yoshida T. 1935. Liver carcinoma induced by feeding O-amidoazotoluene. Arch Pathol Anat 295: 175-220.
89. Scuoppo C, Miething C, Lindqvist L, Reyes J, Ruse C, Appelmann I, Yoon S, Krasnitz A, Teruya-Feldstein J, Pappin D, et al. 2012. A tumour suppressor network relying on the polyamine-hypusine axis. Nature 487: 244-248.
90. Slaga TJ. 1986. SENCAR mouse skin tumorigenesis model versus other strains and stocks of mice. Environ Health Perspect 68: 27-32.
91. Tennant RW, Spalding J, French JE. 1996. Evaluation of transgenic mouse bioassays for identifying carcinogens and noncarcinogens. Mutat Res 365: 119-127.
92. Tennant RW, Stasiewicz S, Mennear J, French JE, Spalding JW. 1999. Genetically altered mouse models for identifying carcinogens. IARC Sci Publ 123-150.
93. Tripodis N, Hart AA, Fijneman RJ, Demant P. 2001. Complexity of lung cancer modifiers: Mapping of thirty genes and twenty-five interactions in half of the mouse genome. J Natl Cancer Inst 93: 1484-1491.
94. Tsai JH, Donaher JL, Murphy DA, Chau S, Yang J. 2012. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 22: 725-736.
95. Tsutsui H. 1918. Uber das kustlich erzeugte cancroid bei der maus. Gann 12: 17-21.
96. Van Dyke T, Jacks T. 2002. Cancer modeling in the modern era: Progress and challenges. Cell 108: 135-144.
97. van Wezel T, Ruivenkamp CA, Stassen AP, Moen CJ, Demant P. 1999. Four new colon cancer susceptibility loci, Scc6 to Scc9 in the mouse. Cancer Res 59: 4216-4218.
98. Venkatachalam S, Shi YP, Jones SN, Vogel H, Bradley A, Pinkel D, Donehower LA. 1998. Retention of wild-type 53 in tumors from p53 heterozygous mice: Reduction of p53 dosage can promote cancer formation. EMBO J 17: 4657-4667.
99. Verma AK, Boutwell RK. 1980. Effects of dose and duration of treatment with the tumour promoting agent, 12-O-tetradecanoylphorbol-13- acetate. Carcinogenesis 1: 271-276.
100. Vineis P, Pirastu R. 1997. Aromatic amines and cancer. Cancer Causes Control 8: 346-355.
101. Vogelstein B, Kinzler KW. 2004. Cancer genes and the pathways they control. Nat Med 10: 789-799.
102. Weisberger EK, Weisburger JH. 1958. Chemistry, carcinogenicity, and metabolism of 2-fluorenamine and related compounds. Adv Cancer Res 5: 331-431.
103. Weisburger JH, Williams GM. 1981. Carcinogen testing: Current problems and new approaches. Science 214: 401-407.
104. Yamagiwa K, Ichikawa K. 1918. Experimental study of the pathogenesis of carcinoma. J Cancer Res 3: 1-29.
105. Zarbl H, Sukumar S, Arthur AV, Martin-Zanca D, Barbacid M. 1985. Direct mutagenesis of Ha-ras-1 oncogenes by N-nitroso-N-methylurea during initiation of mammary carcinogenesis in rats. Nature 315: 382-385.
106. Ziegler A, Jonason AS, Leffell DJ, Simon JA, Sharma HW, Kimmelman J, Jacks T, Brash DE. 1994. Sunburn and p53 in the onset of skin cancer. Nature 372: 773-776.